医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Nativis, Inc. Enters into Evaluation Agreement with Major Japan-Based Pharmaceutical Company

2016年08月03日 PM11:00
このエントリーをはてなブックマークに追加


 

SEATTLE

Nativis, Inc., a clinical stage life sciences company developing non-invasive, medical device therapies for cancers and other serious diseases, today announced that it has entered into an Evaluation Agreement with a major pharmaceutical company based in Japan. The core purpose of the Evaluation Agreement is to confirm the results of both In-Vitro and In-Vivo experiments that have been successfully completed by Nativis at independent research facilities in the United States.

The pharmaceutical company will conduct additional experiments in its labs. Both companies also plan to continue discussions around other potential business opportunities involving Nativis technologies and products in Japan.

“We are very pleased to enter into this agreement,” stated Chris Rivera, Nativis Chairman and Chief Executive Officer. “We look forward to their findings and to our ongoing conversations about other potential collaborations.”

About Nativis, Inc.

Nativis is a clinical stage bioelectronics company, based in Seattle, Washington, that develops non-invasive treatments for cancers and other serious diseases. Nativis utilizes its proprietary Radio Frequency Energy (RFE) technology which regulates defined bioactive targets by specific modulation of charge pathways. RFE modulated control of charge pathways has the potential to significantly change the way cancer and other serious diseases are treated.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160803005527/en/

CONTACT

Nativis, Inc.
Steven Pope, 206-708-2288 ext: 105
spope@nativis.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Samsung Bioepis Announces RENFLEXIS™ (infliximab-abda) Now Available in the United States
  • ニューランド・ラボラトリーズがプロセスエンジニアリング専用ラボを公開
  • 美泰上市全球最先进的人参补剂
  • SpinalCyteが新たな日本国特許を取得
  • Together for Safer Roads任命 David Braunstein担任总裁